Dexcom (DXCM) Operating Expenses (2010 - 2026)

Dexcom (DXCM) has reported Operating Expenses for 17 consecutive years, with $511.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Expenses rose 7.45% year-over-year to $511.7 million in Q2 2026; TTM through Jun 2026 was $2.0 billion, a 6.8% increase from a year earlier, with the FY2025 full-year figure at $1.9 billion, up 2.82% from the prior year.
• Operating Expenses was $511.7 million for Q2 2026 at Dexcom, up from $495.0 million in the prior quarter.
• Over five years, Operating Expenses peaked at $511.7 million in Q2 2026 and troughed at $346.7 million in Q3 2022.
• A 5-year average of $439.9 million and a median of $448.6 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses retreated 11.89% in 2022 and advanced 20.51% in 2023, its largest moves.
• Over 5 years, Operating Expenses stood at $415.9 million in 2022, then rose by 5.72% to $439.7 million in 2023, then gained by 6.19% to $466.9 million in 2024, then increased by 0.6% to $469.7 million in 2025, then increased by 8.94% to $511.7 million in 2026.
• The last three Operating Expenses figures came in at $511.7 million (Q2 2026), $495.0 million (Q1 2026), and $469.7 million (Q4 2025), per Business Quant data.